| アブストラクト | Antibodies targeting the PD-1, PD-L1, and CTLA-4 immune checkpoint axis have been used in a variety of tumor types. They achieve anti-tumor activity through activating the patient's own immune system to target immune response evading cancer cells. However, this unique mechanism of action may cause immune-related adverse events, irAEs. One of these irAEs is myocarditis which is associated with an alarming mortality rate. In this study we presented clinical cases of myocarditis from safety trial datasets submitted to the U.S. Food and Drug Administration, FDA. Additionally, we analyzed over fourteen million FDA Adverse Event Reporting System, FAERS, submissions. The statistical analysis of the FAERS data provided evidence of significantly increased reporting of myocarditis in patients administered immune checkpoint inhibitors alone, in combination with another immune checkpoint inhibitor, the kinase inhibitor axitinib, or chemotherapy, for all cancer types, when compared to patients administered chemotherapy. All combination therapies led to further increased reporting odds ratios of myocarditis. We further analyzed the occurrence of myocarditis by stratifying the reports into sub-cohorts based on specific cancer types and treatment/control groups in major cancer immunotherapy efficacy trials and confirmed the observed trend for each cohort. |
|---|
| 投稿日 | 2021/9/1 |
|---|
| 投稿者 | Makunts, Tigran; Saunders, Ila M; Cohen, Isaac V; Li, Mengxing; Moumedjian, Talar; Issa, Masara A; Burkhart, Keith; Lee, Peter; Patel, Sandip Pravin; Abagyan, Ruben |
|---|
| ジャーナル名 | Scientific reports |
|---|
| 組織名 | Oak Ridge Institute of Science and Education Fellowship at Office of Clinical;Pharmacology, United States Food and Drug Administration, Silver Spring, MA, USA.;Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California;San Diego, La Jolla, CA, USA.;Clinical Pharmacology and Therapeutics (CPT) Postdoctoral Training Program,;University of California San Francisco, San Francisco, CA, USA.;Center for Drug Evaluation and Research, US Food and Drug Administration, Silver;Spring, MA, USA.;Center for Personalized Cancer Therapy, Division of Hematology and Medical;Oncology, UCSD Moores Cancer Center, La Jolla, CA, USA.;San Diego, La Jolla, CA, USA. rabagyan@health.ucsd.edu. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34462476/ |
|---|
